Back to results
US 5,849,863 AGranted
Cytolytic bradykinin antagonists
AssigneesUniversity of Colorado, Cortech, Inc.
InventorsJohn M. Stewart, Daniel C. Chan, Eric T. Whalley, Lajos Gera
Life of this patent
Estimating the term…
Abstract
The present invention provides bradykinin antagonists effective to inhibit cancer cell growth. Also provided are methods of inhibiting lung cancer cell growth by administering a therapeutically effective amount of a dimerized bradykinin antagonist.
Claims20
A bradykinin antagonist compound of the general formula:
- BKA.sub.1 --X--BKA.sub.2,
- wherein BKA.sub.1 and BKA.sub.2 are independently selected from the following:
- Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (SEQ ID NO:1);
- DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg;
- DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg;
- Cys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg;
- .epsilon.-Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg;
- Gun-Gly-8-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu (SEQ ID NO:2);
- Dhq-DArg-Arg-Pro-Hyp-Gly-.epsilon.-Lys-Ser-DCpg-CPg-Arg;
- Dhq-.epsilon.-Lys-DArg-Arg-Pro-Hyp-Gly-Cpg-Ser-DCpg-CPg-Arg;
- DArg-Arg-Pro-Hyp-Gly-Cpg-Ser-DCpg-CPg;
- DArg-Cys-Pro-Hyp-Gly-Cpg-Ser-DCpg-Cpg;
- DArg-Lys-Pro-Hyp-Gly-Cpg-Ser-DCpg-Cpg;
- DArg-Arg-Pro-Hyp-Gly-Cpg-Ser-Tic-Cpg;
- DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Tic-Cpg;
- DArg-Arg-Pro-Hyp-Gly-Cpg-Ser-DTic-Cpg;
- DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Cpg;
- DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic;
- Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Leu;
- DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Leu;
- Gun- DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic;
- DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic;
- Gun- DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic;
- DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-Cpg;
- Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-Cpg;
- Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic;
- Lys- Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic;
- and
- DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic;
- and
- X is a linker group.
28 more elements
A therapeutic method of inhibiting lung cancer cell growth comprising administering to a host in need of such treatment a therapeutically effective amount of one or more of the following compounds.
- BKA.sub.1 --X--BKA.sub.2 I;
- wherein BKA.sub.1 and BKA.sub.2 are the same or different bradykinin antagonists, and
- X is a linker.
Dependencies are inferred from the claim text.